About Subcutaneous RELISTOR
On April 24, 2008, the United States Food and Drug Administration
approved RELISTOR subcutaneous injection for the treatment of OIC in
patients with advanced illness who are receiving palliative care, when
response to laxative therapy has not been sufficient. The use of RELISTOR
beyond four months has not been studied. Wyeth expects to make subcutaneous
RELISTOR available in the United States in early June. Subcutaneous
RELISTOR has also been approved in Canada and is awaiting Australian
approval and European approval, having received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP), the EMEA scientific
committee, in April.
Important Safety Information for Subcutaneous RELISTOR
-- RELISTOR is contraindicated in patients with known or suspected
mechanical gastrointestinal obstruction.
-- If severe or persistent diarrhea occurs during treatment, advise
patients to discontinue therapy with RELISTOR and consult their
-- Use of RELISTOR has not been studied in patients with peritoneal
-- The most common adverse reactions with RELISTOR in clinical trials were
abdominal pain, flatulence, and nausea.
RELISTOR Prescribing Information is available at http://www.relistor.com.
About the Collaboration
In December 2005, Wyeth and Progenics Pharmaceuticals entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects.
About the Companies
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal health,
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved